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Material and Methods: Between July 20011 and July 2015, 
138 patients, 66 men and 72 women, with large brain 
metastases from different solid tumors have been treated 
with HSRT, using Volumetric Modulated Arc Therapy Rapid-
Arc (VMAT-RA) in flattening filter-free (FFF) beams mode. 
The total doses prescribed were 30 Gy in 3 fractions or 30 Gy 
in 5 fractions in relation to the size and site of BM or 30 Gy in 
3 fractions on tumor bed in patients underwent surgical 
resection. 
 
Results: At a median follow-up time of 10.6 months ( range 
2-53 months) 6 (4%) patients had local relapse at a median 
time of 8 months (range 2-53 months) and 45 (32%) patients 
distant brain progression at a median time of 8 months (range 
2-26 months). The 1- and 2-year local control rates were 90% 
and 87% respectively. The 1- and 2-year survival rates were 
72% and 42 % respectively. At the last observation time 99 
/71.7%) patients were alive and 39 (28.3%) dead. Eighty-five 
percent of patients succumbed to their extracranial disease 
and 15% died of progressive intracranial disease. During HSRS 
no increases of corticosteroid or AED have been needed. No 
symptomatic radionecrosis was observed. Factors recorded as 
influencing local failure and worse survival were the presence 
of metastases at diagnosis, NSCLC histology and impossibility 
to surgical resection  
 
Conclusion: HSRS is a safe and effective treatment option for 
patients with large brain metastases. In our series better 
local control was recorded in case of metachronous BM, 
breast cancer histology and patients suitable for surgical 
resection followed by HSRT. 
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Purpose or Objective: To retrospectively evaluate safety and 
brain control (BC) in patients (pts) with 1-4 brain metastases 
(BM) from renal cell carcinoma (RCC) submitted to 
radiosurgery (RS) or fractionated stereotactic radiotherapy 
(FSRT) with or without target therapies (TTs). 
 
Material and Methods: 46 pts with 74 BM were treated. 
Male/female ratio was 31/15, median age was 62y (range, 
29-76). Median KPS was 100% (range, 50-100), 14 (37%), 27 
(59%) and 2 (4%) pts were in RPA class 1, 2 and 3, 
respectively, and 37 (80%) pts had extracranial metastases. 
Disease was controlled in 28 (61%) and in progression in 18 
(39%) pts. Neurologic functional score was generally good 
(NFS=0-2) having only 5 (11%) NFS=3. Relapse was defined 
“in-field” when more than 95% of the recurrence volume was 
within the original 50% isodose, and “out-field” in the other 
cases. Median number of irradiated BM per patient was 1 
(range, 1-4). 37 (80%) pts with 63 BM (85%) received RS at a 
median dose of 20Gy (range, 15-25). Remaining 9 (20%) with 
11 lesions (15%) were underwent FSRT at a dose of 5x6-7Gy. 
21 (46%) pts did not receive TTs, 19 (46%) received 
concomitant and 6 (8%) post- irradiation TTs (sunitinib, 
sorafenib, pazopanib, mTOR inibitors, bevacizumab). 
 
Results: At a median follow-up of 19 months (range, 1-51), 
41 (89%) pts with 66 (89%) BM were evaluable. Local control 
was obtained in 96% of BM: there were complete remission in 
29 (44%), partial remission in 25 (38%), stable disease in 9 
(14%), and progression in 3 (4%) BM. During follow up, 21 
(51%) pts had no brain progression, 4 (10%) had in-field 
relapse, 15 (37%) out-field relapse, and 1 (2%) in- and out-
field relapse. Of 20 (49%) relapsing pts, 14 (70%) were 
retreated with RS, surgery, WBRT and FSRT (8, 3, 2 and 1, 
respectively). In-field relapse occurred after a median time 
of 21.5, out-field relapse after a median time of 8 months. At 
the time of analysis, 39/41 pts (95%) had died, 9 (22%) for 
brain progression, 30 (73%) for systemic progression. Global 
median duration of BC was 22 months (range, 3-51) and 
global median OS from irradiation was 19 months (range, 4-
53). No difference in outcome and toxicity was registered 
comparing pts receiving or not TTs. Deaths due to brain or 
systemic progression occurred after a median time of 12 and 
20 months, respectively. 
 
Conclusion: Effectiveness of RS and FSRT in RCC BM was 
confirmed. The addition of concomitant TTs, though safety, 
does not seem to improve outcomes.  
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Purpose or Objective: to evaluate the local control and 
survival in patients with brain metastases treated with 
stereotactic radiosurgery (SRS) as primary treatment 
approach and to identify predictors of distant brain failure 
(DBF) 
 
Material and Methods: from 2010 to 2014 three hundred and 
eleven brain metastases in 204 consecutive patients were 
treated with SRS at University of Turin. Patients eligible for 
SRS had one to five brain lesions, metastases size ≤ 3 cm, 
Karnofsky performance status ≥ 70 and life expectancy ≥ 3 
months. A total of 172 patients with 266 brain metastases 
were analysed. Doses ranged from 18-24 Gy in single fraction 
related to lesion size. Local control (LC), overall survival (OS) 
and distant brain failure were estimated using the Kaplan-
Meier method. Univariate and multivariate analysis were 
performed to determine the prognostic factors for treatment 
outcomes and DBF 
 
Results: the median follow-up was 24.9 months. The 6- and 
12- month local control rates were 88.5% and 75.1% 
respectively. 46 patients recurred locally after SRS on 55 
brain metastases, with a median time to local failure of 12.1 
months. The median overall survival was 12.8 months, with 
6- and 12- months OS rates of 74.5% and 53.8% respectively. 
On multivariate analysis, no significant prognostic factors 
were associated with local control and survival outcome, 
even if RPA class (I versus II) and metastases diameter 
showed a trend of significance for OS (p=0.11 e p=0.10 
respectively). A distant brain failure was observed in 88 
patients (43.2%), with a median time to DBF of 5.5 months. 
60.8% of these patients maintained an oligometastatic 
intracranial disease (≤ 5 brain lesions ), while 39.2% of 
patients developed multiple brain metastases. Salvage 
therapy was delivered in 46.5% of DBF patients, consisting of 
WBRT in 28.4% of cases and SRS on metastases of new onset 
in 18.1% of patients. However, more than half of patients 
with DBF (53.5%) did not require any salvage treatment. 
Prognostic factors significantly associated with prolonged 
DBF-free survival on multivariate analysis included the 
number of brain metastases <2 (p=0.000) and breast primary 
(p=0.026). Tumor size ≤ 10 mm, s table extracranial disease 
and oligometastatic brain failure were significant predictive 
factors for survival after DBF. 
 
Conclusion: stereotactic radiosurgery is an effective and 
well-tolerated treatment option in patients with 
oligometastatic disease. SRS might also represent a valid 
salvage strategy in patients relapsing in order to delay or 
completely avoid WBRT.  
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